Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: aflibercept (AVE0005)
Drug: placebo

First Posted Date: 2009-04-06

Last Posted Date: 2016-05-05

Lead Sponsor: Sanofi

Target Recruit Count: 88

Registration Number: NCT00876044

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lixisenatide (AVE0010)
Drug: Placebo
Device: Pen auto-injector
Drug: Sulfonylurea
Drug: Basal Insulin

First Posted Date: 2009-03-20

Last Posted Date: 2016-10-11

Lead Sponsor: Sanofi

Target Recruit Count: 311

Registration Number: NCT00866658

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan

Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease

Phase 3

Completed

Conditions: Peripheral Arterial Disease (PAD)

Interventions: Drug: clopidogrel (SR25990)
Drug: ticlopidine

First Posted Date: 2009-03-16

Last Posted Date: 2012-07-17

Lead Sponsor: Sanofi

Target Recruit Count: 431

Registration Number: NCT00862420

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorders

Interventions: Drug: amibegron (SR58611A)

First Posted Date: 2009-03-04

Last Posted Date: 2009-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 527

Registration Number: NCT00855530

Locations: 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Sitagliptin
Drug: Metformin

First Posted Date: 2009-02-26

Last Posted Date: 2012-10-04

Lead Sponsor: Sanofi

Target Recruit Count: 112

Registration Number: NCT00851903

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms
Neoplasm Metastasis

Interventions: Drug: aflibercept
Drug: oxaliplatin
Drug: 5-FU
Drug: Folinic Acid

First Posted Date: 2009-02-25

Last Posted Date: 2016-06-07

Lead Sponsor: Sanofi

Target Recruit Count: 268

Registration Number: NCT00851084

Locations: 🇦🇺
Sanofi-Aventis Investigational Site Number 036001, Hunter Region Mail Centre, Australia
🇩🇪
Sanofi-Aventis Investigational Site Number 276001, Hannover, Germany
🇪🇸
Sanofi-Aventis Investigational Site Number 724002, Sabadell, Spain

and more 34 locations

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Drug: Irbesartan 150mg

First Posted Date: 2009-02-19

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 968

Registration Number: NCT00847834

Locations: 🇨🇳
Sanofi aventis administrative office, Beijing, China

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Phase 2

Completed

Conditions: Influenza
Orthomyxoviruses
Myxovirus Infection

Interventions: Biological: Influenza virus vaccine - cell based (2007-2008 Formulation)
Biological: Influenza virus vaccine - cell-based (2007-2008 Formulation)
Biological: Influenza virus vaccine (2007-2008 Formulation)

First Posted Date: 2009-02-18

Last Posted Date: 2012-12-19

Lead Sponsor: Sanofi

Target Recruit Count: 729

Registration Number: NCT00845429

China Medical University Hospital (CMUH) Triapin Listing

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Ramipril + Felodipine
Drug: Ramipril

First Posted Date: 2009-02-11

Last Posted Date: 2010-08-27

Lead Sponsor: Sanofi

Target Recruit Count: 49

Registration Number: NCT00841880

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

Phase 3

Completed

Conditions: Heart Defects, Congenital

Interventions: Drug: placebo
Drug: Clopidogrel

First Posted Date: 2009-02-02

Last Posted Date: 2011-08-22

Lead Sponsor: Sanofi

Target Recruit Count: 49

Registration Number: NCT00833703

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Home Terms & Conditions Privacy Policy